Kymriah's manufacturing issues are well known. In the JULIET trial, there were 11 manufacturing failures out of 160 compared to 1 Yescarta manufacturing failure in 111 patients.
At ASH, real world Yescarta use was presented from a subset of centers. Of 295 patients, 7 had manufacturing failures (~2%) while 12 others died prior to infusion.
just added a bunch of EU sites. This is 2nd line treatment. And now this...
for FIRST LINE treatment was also recently posted as RECRUITING!!! n=40. I see this as a really really good sign. There is the belief that earlier treatment will result in enhanced efficacy because the cells are healthier. That's what insurers have been asking for and will lead to a much greater treatment population.
For now, I don't see Kymriah taking away much marketshare from Yescarta in NHL.
They also have done some renaming. KTE-C19 is the name for Yescarta in approved indications (NHL); KTE-X19 is the name for Yescarta in not yet approved indications (ALL, CLL, etc)